Paper36769018
Application of Antisense Conjugates for the Treatment of Myotonic Dystrophy Type 1.
Stoodley J and 5 others. Int J Mol Sci, 2023. Cited by 18 papers, by iCite.
Cite this record
ConductScience Library. Application of Antisense Conjugates for the Treatment of Myotonic Dystrophy Type 1. Papers, record 36769018. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36769018
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Myotonic Dystrophy | Major topic |
| Muscular Dystrophies | Major topic |
| Mice | |
| Animals | |
| Tissue Distribution | |
| Oligonucleotides, Antisense | |
| Myocardium |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| MR/P01741X/1 | Medical Research Council | United Kingdom | PubMed | |
| MR/W014742/1 | Medical Research Council | United Kingdom | PubMed |
Source PubMed
References98
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22861906 | Psychiatric and cognitive phenotype of childhood myotonic dystrophy type 1. | Dev Med Child Neurol | 2012 | https://conductscience.org/library/papers/22861906 | PubMed |
| 2 | 8378346 | Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. | Proc Natl Acad Sci U S A | 1993 | https://conductscience.org/library/papers/8378346 | PubMed |
| 3 | 34385691 | Cholesterol-functionalized DNA/RNA heteroduplexes cross the blood-brain barrier and knock down genes in the rodent CNS. | Nat Biotechnol | 2021 | https://conductscience.org/library/papers/34385691 | PubMed |
| 4 | 12240255 | 3'-amino-2',4'-BNA: novel bridged nucleic acids having an N3'-->P5' phosphoramidate linkage. | Chem Commun (Camb) | 2001 | https://conductscience.org/library/papers/12240255 | PubMed |
| 5 | 10655554 | Dramatic, expansion-biased, age-dependent, tissue-specific somatic mosaicism in a transgenic mouse model of triplet repeat instability. | Hum Mol Genet | 2000 | https://conductscience.org/library/papers/10655554 | PubMed |
| 6 | 33821570 | Delivery of oligonucleotide-based therapeutics: challenges and opportunities. | EMBO Mol Med | 2021 | https://conductscience.org/library/papers/33821570 | PubMed |
| 7 | 31479430 | Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice. | J Clin Invest | 2019 | https://conductscience.org/library/papers/31479430 | PubMed |
| 8 | 25753670 | Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy. | Nucleic Acids Res | 2015 | https://conductscience.org/library/papers/25753670 | PubMed |
| 9 | 18784278 | Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. | Hum Mol Genet | 2008 | https://conductscience.org/library/papers/18784278 | PubMed |
| 10 | 11359466 | Epidemiology of myotonic dystrophy in Italy: re-apprisal after genetic diagnosis. | Clin Genet | 2001 | https://conductscience.org/library/papers/11359466 | PubMed |
| 11 | 31376426 | Targeting the transferrin receptor for brain drug delivery. | Prog Neurobiol | 2019 | https://conductscience.org/library/papers/31376426 | PubMed |
| 12 | 11528389 | Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. | Nat Genet | 2001 | https://conductscience.org/library/papers/11528389 | PubMed |
| 13 | 1303233 | Correlation between CTG trinucleotide repeat length and frequency of severe congenital myotonic dystrophy. | Nat Genet | 1992 | https://conductscience.org/library/papers/1303233 | PubMed |
| 14 | 20603324 | CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. | Hum Mol Genet | 2010 | https://conductscience.org/library/papers/20603324 | PubMed |
| 15 | 7896884 | Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. | J Cell Biol | 1995 | https://conductscience.org/library/papers/7896884 | PubMed |
| 16 | 19767415 | Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. | Brain | 2009 | https://conductscience.org/library/papers/19767415 | PubMed |
| 17 | 8196473 | Blockade of morphine analgesia by an antisense oligodeoxynucleotide against the mu receptor. | Life Sci | 1994 | https://conductscience.org/library/papers/8196473 | PubMed |
| 18 | 32242217 | Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA. | Hum Mol Genet | 2020 | https://conductscience.org/library/papers/32242217 | PubMed |
| 19 | 28009628 | Enhanced delivery of IL-1 receptor antagonist to the central nervous system as a novel anti-transferrin receptor-IL-1RA fusion reverses neuropathic mechanical hypersensitivity. | Pain | 2017 | https://conductscience.org/library/papers/28009628 | PubMed |
| 20 | 28624222 | Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice. | Mol Ther Nucleic Acids | 2017 | https://conductscience.org/library/papers/28624222 | PubMed |
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42339623 | Bottlebrush polymer conjugates for enhanced antisense oligonucleotide therapy in myotonic dystrophy type 1. | Nucleic Acids Res | 2026 | https://conductscience.org/library/papers/42339623 | PubMed |
| 41996006 | Therapeutic Strategies Targeting the Molecular Pathogenesis of Myotonic Dystrophy Type 1: Current Status and Future Directions. | Mol Diagn Ther | 2026 | https://conductscience.org/library/papers/41996006 | PubMed |
| 41797662 | Targeting Expanded CUG and CTG Repeats as a Therapeutic Approach for Myotonic Dystrophy Type 1 (DM1). | ChemMedChem | 2026 | https://conductscience.org/library/papers/41797662 | PubMed |
| 40938889 | Validation of the FVB/N-Tg(HSA* LR)20bCath mice of myotonic dystrophy using swallowing function assessment, histology, and immunofluorescence analysis. | PLoS One | 2025 | https://conductscience.org/library/papers/40938889 | PubMed |
| 40808372 | Changes in RNA splicing as a surrogate endpoint for myotonic dystrophy Type 1 (DM1) clinical trials. | J Neuromuscul Dis | 2026 | https://conductscience.org/library/papers/40808372 | PubMed |
| 40608957 | Exon skipping peptide-conjugated morpholinos downregulate dynamin 2 to rescue centronuclear myopathy. | Brain | 2025 | https://conductscience.org/library/papers/40608957 | PubMed |
| 40508159 | Multisystem Symptoms in Myotonic Dystrophy Type 1: A Management and Therapeutic Perspective. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40508159 | PubMed |
| 40367190 | Intra-amniotic antisense oligonucleotide treatment improves phenotypes in preclinical models of spinal muscular atrophy. | Sci Transl Med | 2025 | https://conductscience.org/library/papers/40367190 | PubMed |
| 39910928 | Targeting Drug Delivery System to Skeletal Muscles: A Comprehensive Review of Different Approaches. | J Cachexia Sarcopenia Muscle | 2025 | https://conductscience.org/library/papers/39910928 | PubMed |
| 39565688 | CRISPR Diagnostics for Quantification and Rapid Diagnosis of Myotonic Dystrophy Type 1 Repeat Expansion Disorders. | ACS Synth Biol | 2024 | https://conductscience.org/library/papers/39565688 | PubMed |
| 38501046 | Structure-activity relationship study of mesyl and busyl phosphoramidate antisense oligonucleotides for unaided and PSMA-mediated uptake into prostate cancer cells. | Front Chem | 2024 | https://conductscience.org/library/papers/38501046 | PubMed |
| 38443798 | Curriculum vitae of CUG binding protein 1 (CELF1) in homeostasis and diseases: a systematic review. | Cell Mol Biol Lett | 2024 | https://conductscience.org/library/papers/38443798 | PubMed |
| 38165037 | Combinatorial effects of ion channel mis-splicing as a cause of myopathy in myotonic dystrophy. | J Clin Invest | 2024 | https://conductscience.org/library/papers/38165037 | PubMed |
| 37221259 | [Molecular therapies: present and future in neuromuscular diseases]. | Nervenarzt | 2023 | https://conductscience.org/library/papers/37221259 | PubMed |
Genes15
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36769018
GET https://conductscience.org/api/papers/v1/36769018/references?page=2